A news story circulating in early 2025 sparked widespread curiosity in obesity medicine circles and patient communities alike: speculation that a prominent public figure may have gained access to retatrutide — the investigational triple agonist from Eli Lilly — through a little-known FDA program designed for experimental treatments. The White House subsequently batted down those claims, but the episode opened a genuinely important conversation about how unapproved drugs reach patients outside of clinical trials, and what that means for the thousands of people currently waiting for retatrutide to become available. Ground News covered the story in detail.
The short answer is no. Retatrutide — manufactured by Eli Lilly and Company under the compound name LY3437943, and commonly referred to as reta in patient communities — is not FDA approved as of April 2026. No New Drug Application (NDA) has been filed with the FDA, and no approval timeline has been publicly confirmed by Eli Lilly.
What does exist is an extraordinarily promising clinical data package. The Phase 2 trial published in the New England Journal of Medicine in 2023 demonstrated mean weight loss of up to 24.2% at 48 weeks in the highest-dose group — results that were, at the time, unprecedented for a pharmacologic obesity treatment. Then came the TRIUMPH-4 Phase 3 trial results, announced by Eli Lilly in December 2025: participants receiving the 12mg maintenance dose achieved a mean weight loss of 28.7% over 68 weeks — the highest ever recorded in a Phase 3 obesity clinical trial.
For context, the retatrutide Phase 3 data meaningfully outpaces both semaglutide (STEP-1: approximately 14.9% mean weight loss at 68 weeks) and tirzepatide (SURMOUNT-1: approximately 20.9% mean weight loss at 72 weeks at the 15mg dose). Yet despite these results, reta remains investigational. A peer-reviewed Phase 3 publication was still pending as of April 2026.
The FDA compassionate use program — formally called Expanded Access — is a regulatory pathway that allows patients with serious or life-threatening conditions to access investigational drugs, biologics, or medical devices outside of a clinical trial. It is not a shortcut or a loophole; it requires formal FDA review, typically an Institutional Review Board (IRB) determination, and — critically — the cooperation and approval of the drug's manufacturer.
There are several forms of expanded access:
In practice, expanded access for obesity drugs is exceedingly rare. The program was historically designed for conditions like terminal cancers or rare diseases with no other treatment options. Obesity, while a serious chronic disease with significant mortality implications, would face a high bar for individual compassionate use approval — particularly for a drug in active Phase 3 development where clinical trial enrollment pathways exist.
Speculation arose that a prominent public figure may have received retatrutide through the FDA's expanded access pathway — essentially a compassionate use approval for an individual patient. The White House denied these reports, and Eli Lilly has not commented publicly on any such arrangement.
The episode is instructive regardless of its accuracy. It highlights that the FDA compassionate use program exists as a legitimate, if narrow, pathway for unapproved drugs. It also illustrates just how much public and political interest surrounds retatrutide specifically — a drug that, based on TRIUMPH-4 data, has now demonstrated weight loss results that the scientific community has never seen from a once-weekly injectable medication.
What the story does not mean: that compassionate use is a broadly accessible option for patients interested in reta. The regulatory, logistical, and manufacturer-approval requirements make individual expanded access an extraordinary circumstance, not a routine one.
For most patients, the path to retatrutide runs through the standard FDA approval and commercial launch process. Understanding where reta stands relative to other approved options helps frame realistic expectations.
| Drug | Mechanism | Trial Duration | Mean Weight Loss (Highest Dose) | FDA Approval Status |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | 68 weeks (STEP-1) | ~14.9% | FDA approved |
| Tirzepatide (Zepbound) | GLP-1 / GIP dual agonist | 72 weeks (SURMOUNT-1) | ~20.9% (15mg) | FDA approved |
| Retatrutide (LY3437943) | GLP-1 / GIP / glucagon triple agonist | 68 weeks (TRIUMPH-4) | 28.7% (12mg) | Not FDA approved; NDA not yet filed |
The TRIUMPH-4 results represent a genuine inflection point in obesity pharmacotherapy. A 28.7% mean weight loss over 68 weeks — achieved with the so-called triple G mechanism targeting GLP-1, GIP, and glucagon receptors simultaneously — approaches the weight loss territory historically associated with bariatric surgery. For patients who have struggled with food noise, weight regain, and the limitations of currently approved options, these data carry meaningful clinical weight.
It is also worth noting the adverse event profile from TRIUMPH-4: dysesthesia (an abnormal skin sensation) occurred in 20.9% of participants at the 12mg dose versus 0.7% on placebo, and discontinuation rates were 18.2% at 12mg compared to 4.0% on placebo. Some discontinuations were reportedly due to perceived excessive weight loss — a finding without precedent in obesity trial history. These are important considerations for any informed conversation about reta's risk-benefit profile once it reaches clinical practice.
The compassionate use story, whether accurate or not, underscores a broader truth: retatrutide has captured attention at every level — from patient communities to the highest offices in the country. The clinical data justify that attention. The approval timeline does not yet have a confirmed endpoint, but the trajectory is clear.
Joining the glp3md waitlist is the most direct way to stay informed as the regulatory picture evolves. Visit glp3md.com to add your name and receive updates on retatrutide's approval status, TRIUMPH-4 peer-reviewed publication, and what access may look like post-approval. Please note: joining the waitlist carries no promises or guarantees regarding medication availability, treatment, or prescriptions. Retatrutide is not FDA approved, and the waitlist is an informational resource only. But staying informed — especially for a drug with data this compelling — is a step worth taking.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.